
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, announced completion of enrollment in NB-303 and NB-304, the final two Phase III clinical trials for Contrave®, its lead obesity product candidate.
Click here for full Story http://www.medicalnewstoday.com/articles/106917.php |